Therapieverlaufskontrolle nach Chemotherapie an Tumoren des Menschen mit Hilfe der In-vivo-31P-Spektroskopie

  • W. Semmler
  • G. Gademann
  • P. Bachert-Baumann
  • H.-J. Zabel
  • W.-J. Lorenz
  • G. van Kaick
Conference paper

Zusammenfassung

Die Therapieverlaufskontrolle ist eine Routineaufgabe in der onkologischen Praxis und wird vorwiegend mit bildgebenden Verfahren durchgeführt. Der Kontrollparameter ist im allgemeinen die Tumorgröße. Die Größenreduktion des Tumors setzt im allgemeinen erst in einem Zeitraum von mehreren Tagen – meist Wochen – nach Beginn der Therapie ein.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bárány M, Glonek T (1984) Identification of diseased states by phosphorus-31 NMR. In: Gohrenstein DG (ed) Phosphorus-31 NMR, principles and applications. Academic Press, London, pp 511–545Google Scholar
  2. 2.
    Evanochko WT, Ng TC, Lilly MB, Lawson AJ, Corbett TH, Durant JR, Glickson JD (1983) In vivo 31P NMR study of the metabolism of murine mamary 16/C adenocar-cinoma and its response to chemotherapy, x-radiation, and hyperthermia. Proc Natl Acad Sci USA 80:334–338PubMedCrossRefGoogle Scholar
  3. 3.
    Just M, Gutjahr P, Juretschke HP, Dittrich N, Higer HP, Klose KJ, Ritter G (1987) 31Phosphor-Spektroskopie bei osteogenem Sarkom. Fortschr Rontgenstr 146:144–148CrossRefGoogle Scholar
  4. 4.
    Naruse S, Horikawa Y, Tanaka C, Higuchi T, Ueda S, Hirakawa K, Nishikawa H, Watari H (1985) Observations of energy metabolism in neuroectodermal tumors using in vivo 31P-NMR. Magn Reson Imag 3:117–123CrossRefGoogle Scholar
  5. 5.
    Ng TC, Evanochko WT, Hiramoto RN, Ghanta VK, Lilly MB, Lawson AJ, Corbett TH, Durant JR, Glickson JD (1982) 31P-NMR spectroscopy of in vivo tumors. J Magn Reson 49:271–286CrossRefGoogle Scholar
  6. 6.
    Ng TC, Majors AW, Meany TF (1986) In vivo MR spectroscopy of human subjects with a 1.4-T whole body MR imager. Radiology 158:517–520PubMedGoogle Scholar
  7. 7.
    Nidecker AC, Müller S, Aue WP, Seelig J, Fridrich R, Remagen W, Hartweg H, Benz UF (1985) Extremity bone tumors: evaluation by P-31 MR spectroscopy. Radiology 157:167–174PubMedGoogle Scholar
  8. 8.
    Oberhaensli RD, Gallowy GJ, Talor DJ, Bore PJ, Rajagopalan B, Radda GK (1986) First year of experience with 31 magnetic resonance studies of human liver. Magn Res Imag 4:413–416CrossRefGoogle Scholar
  9. Oberhaensli RD, Bore PJ, Rampling RP, Hilton-Jones D, Hands LJ, Radda GK (1986) Biochemical investigation of human tumours in-vivo with phosphorus-31 magnetic resonance spectroscopy. Lancet 11:8–11CrossRefGoogle Scholar
  10. 9..
    Semmler W, Gademann G, Schlag P, Bachert-Baumann P, Zabel H-J, Lorenz WJ, van Kaick G (to be published) Impact of hyperthermic regional perfusion therapy on cell metabolism of malignant melanoma monitored by 3’P-MR spectroscopy. Mag Res Imag (to be published)Google Scholar
  11. 10..
    Semmler W, Gademann G, Bachert-Baumann P, Zabel H-J, Lorenz WJ, van Kaick G (to be published) Monitoring of human tumor response to therapy by means of 31P-MR spectroscopy. Radiology (to be published)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • W. Semmler
  • G. Gademann
  • P. Bachert-Baumann
  • H.-J. Zabel
  • W.-J. Lorenz
  • G. van Kaick

There are no affiliations available

Personalised recommendations